FI51936C - Förfarande för framställning av terapeutiskt användbara 3,4-dihydronaf talenonoxi-2-hydroxipropylaminer samt av dessas syra-additionssalter. - Google Patents

Förfarande för framställning av terapeutiskt användbara 3,4-dihydronaf talenonoxi-2-hydroxipropylaminer samt av dessas syra-additionssalter.

Info

Publication number
FI51936C
FI51936C FI692717A FI271769A FI51936C FI 51936 C FI51936 C FI 51936C FI 692717 A FI692717 A FI 692717A FI 271769 A FI271769 A FI 271769A FI 51936 C FI51936 C FI 51936C
Authority
FI
Finland
Prior art keywords
dihydronaphthalenoxyoxy
hydroxypropylamines
preparation
acid addition
addition salts
Prior art date
Application number
FI692717A
Other languages
English (en)
Finnish (fi)
Other versions
FI51936B (sv
Inventor
Jr John Shavel
Sheldon Farber
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to FI762870A priority Critical patent/FI762870A/fi
Publication of FI51936B publication Critical patent/FI51936B/fi
Application granted granted Critical
Publication of FI51936C publication Critical patent/FI51936C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/38—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI692717A 1968-09-23 1969-09-23 Förfarande för framställning av terapeutiskt användbara 3,4-dihydronaf talenonoxi-2-hydroxipropylaminer samt av dessas syra-additionssalter. FI51936C (sv)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI762870A FI762870A (sv) 1968-09-23 1976-10-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76185768A 1968-09-23 1968-09-23

Publications (2)

Publication Number Publication Date
FI51936B FI51936B (sv) 1977-01-31
FI51936C true FI51936C (sv) 1977-05-10

Family

ID=25063434

Family Applications (1)

Application Number Title Priority Date Filing Date
FI692717A FI51936C (sv) 1968-09-23 1969-09-23 Förfarande för framställning av terapeutiskt användbara 3,4-dihydronaf talenonoxi-2-hydroxipropylaminer samt av dessas syra-additionssalter.

Country Status (15)

Country Link
US (1) US3641152A (sv)
JP (1) JPS4843734B1 (sv)
BE (1) BE739195A (sv)
CH (1) CH525183A (sv)
DE (2) DE1967162C3 (sv)
DK (2) DK125588B (sv)
ES (1) ES371737A1 (sv)
FI (1) FI51936C (sv)
FR (1) FR2018626B1 (sv)
GB (1) GB1223527A (sv)
IT (1) IT1033032B (sv)
NL (1) NL139166B (sv)
NO (1) NO128869B (sv)
SE (1) SE362414B (sv)
ZA (1) ZA695648B (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755071A (fr) * 1969-09-17 1971-02-22 Warner Lambert Pharmaceutical Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone
US3959486A (en) * 1970-05-27 1976-05-25 Imperial Chemical Industries Limited Method for producing β-adrenergic blockage with alkanolamine derivatives
DE2130393C3 (de) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2119843B1 (sv) * 1970-12-28 1974-03-22 Laroche Navarro Labo
JPS5122737Y2 (sv) * 1972-12-30 1976-06-11
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
GB1493848A (en) * 1975-07-24 1977-11-30 Beecham Group Ltd Aryltetralins
CH621330A5 (sv) * 1976-05-14 1981-01-30 Sandoz Ag
DE2810869A1 (de) * 1977-03-24 1978-09-28 Sandoz Ag 3-amino-2-hydroxypropoxy-derivate, ihre herstellung und verwendung
US4176183A (en) * 1977-05-02 1979-11-27 Merck & Co., Inc. Novel naphthyridines
US4270005A (en) * 1977-11-14 1981-05-26 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
CH641147A5 (de) * 1979-01-17 1984-02-15 Sandoz Ag 3-amino-2-hydroxypropoxyaryl-derivat, seine herstellung und dieses enthaltende heilmittel.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
FR2507181A1 (fr) * 1981-06-05 1982-12-10 Sanofi Sa Nouveaux ethers de phenol actifs sur le systeme cardiovasculaire, leur procede de preparation et leur utilisation dans des medicaments
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
ES2065278B1 (es) * 1993-06-24 1995-09-01 Medichem Sa Procedimiento de obtencion enantioselectivo del levobunolol.
AU2001279050B2 (en) * 2000-07-27 2006-10-19 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1023214A (en) 1962-12-17 1966-03-23 Ici Ltd Carbocyclic hydroxyamines

Also Published As

Publication number Publication date
DE1948144C3 (de) 1980-01-17
DK128536B (da) 1974-05-20
DK125588B (da) 1973-03-12
CH525183A (de) 1972-07-15
NO128869B (sv) 1974-01-21
NL6914077A (sv) 1970-03-25
FR2018626A1 (sv) 1970-06-26
FI51936B (sv) 1977-01-31
JPS4843734B1 (sv) 1973-12-20
NL139166B (nl) 1973-06-15
ES371737A1 (es) 1972-03-16
DE1948144B2 (de) 1979-05-03
ZA695648B (en) 1971-03-31
FR2018626B1 (sv) 1973-06-08
US3641152A (en) 1972-02-08
IT1033032B (it) 1979-07-10
DE1967162C3 (de) 1981-03-19
GB1223527A (en) 1971-02-24
DE1948144A1 (de) 1970-03-26
SE362414B (sv) 1973-12-10
BE739195A (sv) 1970-03-23
DE1967162B1 (de) 1980-07-31

Similar Documents

Publication Publication Date Title
FI48731C (sv) Förfarande för framställning av terapeutiskt användbara, i 1-ställning med en aminoalkylgrupp substituerade ftalaner och iso-kromaner.
FI49300C (sv) Förfarande för framställning av terapeutiskt aktiva 1,4-dihydropyridin derivater.
FI51190C (sv) Förfarande för framställning av terapeutiskt verksamma, i synnerhet co ronardilatoriska N-(3,4,5-trimetoxi-cinnamoyl)-piperazinderivater.
FI51936C (sv) Förfarande för framställning av terapeutiskt användbara 3,4-dihydronaf talenonoxi-2-hydroxipropylaminer samt av dessas syra-additionssalter.
FI51350C (sv) Förfarande för framställning av 6-sulfamyl-1,2,3,4-tetrahydro-4-kinazo linoner och deras salter med diuretiska egenskaper.
FI52339C (sv) Förfarande för framställning av terapeutiskt aktiva 1,4-dihydropyridin derivat.
CH546788A (fr) Procede de preparation d'agents anti-inflammatoires.
FI49977C (sv) Förfarande för framställning av terapeutiskt användbara 3-alkoxy-tiana ften-2-karboxyamider och deras 1,1-dioxider
FI52338C (sv) Förfarande för framställning av terapeutiskt användbara 1,2,3,6-tetrah ydropyridinderivat och deras syraadditionssalter.
FI49720C (sv) Förfarande för framställning av terapeutiskt verksamma 2-metyl-3-karbo nsyraamidokinoxalin-di-N-oxider-(1,4).
FI52715C (sv) Förfarande för framställning av terapeutiskt användbara vitamin A-syra -amider.
FI48728C (sv) Analogiförfarande för framställning av terapeutiskt användbara fenylät tiksyraderivat.
FI49827C (sv) Förfarande för framställning av substituerade 3-hydroximetyl-isokinoli ner med terapeutisk verkan.
IL36435A (en) Methyl 7-o-methyl-6,8-dideoxy-6-(trans-1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside,the acid addition salts thereof and the production of these
FI51176C (sv) Förfarande för framställning av terapeutiskt användbara 4-aryl-1-(4,4- diarylbutyl)-4-hydroxipiperidiner och dessas syraadditionssalter.
FI51479C (sv) Förfarande för framställning av en terapeutisk användbar 3,3-disubstit uerad hexahydro-1H-azepinförening.
FI49718C (sv) Förfarande för framställning av terapeutiskt verksamma 2-halogenmetyl- 3-karbonsyraamidokinoxalin-di-N-oxider-(1,4)
FI49166C (sv) Förfarande för framställning av en beta-stimulerande 6,7-diacyloxi-tet rahydroisokinolinförening och dess farmaceutiskt acceptabla syraadditi onssalt.
IL31910A0 (en) Indenopyridines,their acid addition salts,and the production thereof
FI51349C (sv) Förfarande för framställning av terapeutiskt verksamma N-substituerade 6,7-bensomorfaner.
BR7105511D0 (pt) Processo para a preparacao de derivados 1,4 benzodiazepinicos
FI49417C (sv) Förfarande för framställning av farmakologiskt aktiva 2,3-dihydro-bens ofuran-2-karbonsyror.
FI45450C (sv) Förfarande för framställning av terapeutiskt användbara fentiazinderiv at och salter därav
FI45175C (sv) Förfarande för framställning av 18-metyl-19-nor-17alfa-hydroxi-progest eroner och deras 17alfa-estrar.
FI45555C (sv) Förfarande för framställning av terapeutiskt användbara hjärtglykosidd erivat av strofantidintyp.